Chief Executive Officer
Mr. Stephan Jackman, Chief Executive Officer of Alzamend Neuro™, with over twenty years of multi-industry experience in administration, business and product development, marketing, project and program management, and strategic planning, provides a dynamic blend of bio-pharma experience and corporate leadership to navigate the challenges commonly faced by a developmental biotech company. He has played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization with the dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals.
Kenneth S. Cragun
Chief Financial Officer
Recently, Mr. Cragun served as a CFO Partner at Hardesty, LLC, a national executive services firm since October 2016. His assignments at Hardesty, LLC included serving as CFO of CorVel Corporation, a $1.1 billion market cap publicly traded company (NASDAQ: CRVL) and a nationwide leader in technology driven, healthcare-related, risk management programs and of RISA Tech, Inc. a private structural design and optimization software company. Cragun was also CFO of two NASDAQ-listed companies: Local Corporation, from April 2009 to September 2016, which operated Local.com, a U.S. top 100 website; and Modtech Holdings, Inc., from June 2006 to March 2009, a supplier of modular buildings.
Henry C. W. Nisser Esq.
Executive Vice President, General Counsel and Corporate Secretary
Mr. Henry Nisser, Esq., Executive Vice President, General Counsel and Corporate Secretary, has served Alzamend since May 1, 2019. From October 31, 2011 through April 26, 2019, Mr. Nisser was an associate and, subsequently, a partner with Sichenzia Ross Ference LLP (“SRF”), a law firm based in New York City.
While with SRF, his practice was concentrated in national and international corporate law, with a particular focus on U.S. securities compliance, public as well as private M&A, equity and debt financings and corporate governance. Mr. Nisser drafted and negotiated a variety of agreements related to reorganizations, share and asset purchases, indentures, public and private offerings, tender offers and going private transactions. Mr. Nisser also represented clients’ special committees established to evaluate M&A transactions and advised such committees’ members with respect to their fiduciary duties.
Mr. Nisser is fluent in French and Swedish as well as conversant in Italian. Mr. Nisser received his B.A. from Connecticut College in 1992, where he majored in International Relations and Economics. He received his LLB from the University of Buckingham School of Law in 1999.
Board Of Directors
Milton “Todd” Ault, III
Mr. Ault founded Alzamend Neuro™, Inc., a biotechnology firm dedicated to finding the treatment, prevention and cure for Alzheimer’s Disease on February 26, 2016 and has served as its Chairman ever since.
Mr. Ault is a seasoned business professional and entrepreneur who has spent more than twenty-seven years identifying value in various financial markets including equities, fixed income, commodities, and real estate. On March 16, 2017, Mr. Ault was appointed Executive Chairman of the Board for DPW Holdings, Inc. (“DPW”), formerly known as Digital Power Corporation and on December 28, 2017,
William B. Horne
Mr. Horne has served as a director for Alzamend Neuro™ since June 01, 2016 and was its Chief Financial Officer from this same time until December 15, 2018. Mr. Horne is a member of the board of directors of DPW Holdings, Inc. (NYSE.Mkt: DPW) since October 2016 and on January 25, 2018, Mr. Horne was appointed as DPW Holdings Chief Financial Officer. Mr. Horne is the Chief Financial Officer, Treasurer and a member of the Board of Directors for Avalanche International, Corp dba MTIX International, Inc., a publicly traded company and has held the same positions for Ault & Company, Inc., a private holding company, since January 2018
Philip E. Mansour
Mr. Mansour the company’s former Chief Executive Officer and current member of the Board of Directors, has been leading the efforts to establish the Company, its Board of Directors, hire and contract with all appropriate FDA consulting firms, as well as establish and negotiate all relationships with the scientific and academic community.
Mr. Mansour has been actively involved with disruptive technologies as an inventor, manager, executive and coach for more than 3 decades. During that period, he has driven innovation and inspired collaboration among facilities in seven states and four continents. He is a master of operations, organizational change management, and integrations.
Scientific Advisory Board
Thomas M. Wisniewski, MD
Dr. Thomas Wisniewski is a board-certified neurologist and neuropathologist and is the Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment. Dr. Wisniewski operates an active research laboratory focusing on neurodegenerative disorders with a particular focus on the mechanisms that drive amyloid deposition in Alzheimer’s and prion diseases. This work has led to over 300 peer-reviewed publications, 25 issued patents, and continuous funding from the NIH for over 26 years.
Eric M. McDade, DO
Dr. Eric McDade is a board-certified cognitive neurologist that has focused his activities on the evaluation of those with dementia syndromes and on developing a clinical research program that focuses on using brain imaging and cerebrospinal fluid markers to identify those at risk for Alzheimer disease.